CA3118361A1 - Antibodies against mfap4 - Google Patents

Antibodies against mfap4 Download PDF

Info

Publication number
CA3118361A1
CA3118361A1 CA3118361A CA3118361A CA3118361A1 CA 3118361 A1 CA3118361 A1 CA 3118361A1 CA 3118361 A CA3118361 A CA 3118361A CA 3118361 A CA3118361 A CA 3118361A CA 3118361 A1 CA3118361 A1 CA 3118361A1
Authority
CA
Canada
Prior art keywords
seq
ligand
antibody
mfap4
has0326
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3118361A
Other languages
English (en)
French (fr)
Inventor
Grith Lykke Sorensen
Anders Schlosser
Uffe Holmskov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern Denmark
Original Assignee
University of Southern Denmark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern Denmark filed Critical University of Southern Denmark
Publication of CA3118361A1 publication Critical patent/CA3118361A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3118361A 2017-11-01 2018-11-01 Antibodies against mfap4 Pending CA3118361A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17199552.5 2017-11-01
EP17199552 2017-11-01
PCT/EP2018/079949 WO2019086580A1 (en) 2017-11-01 2018-11-01 Antibodies against mfap4

Publications (1)

Publication Number Publication Date
CA3118361A1 true CA3118361A1 (en) 2019-05-09

Family

ID=60201899

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3118361A Pending CA3118361A1 (en) 2017-11-01 2018-11-01 Antibodies against mfap4

Country Status (7)

Country Link
US (1) US11993649B2 (cg-RX-API-DMAC10.html)
EP (1) EP3704147A1 (cg-RX-API-DMAC10.html)
JP (1) JP7382343B2 (cg-RX-API-DMAC10.html)
CN (1) CN111315771B (cg-RX-API-DMAC10.html)
AU (1) AU2018359635B2 (cg-RX-API-DMAC10.html)
CA (1) CA3118361A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019086580A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022218908A1 (en) 2021-04-12 2022-10-20 Syddansk Universitet Mfap4 and treatment of fibrosis
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体偶联药物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059097A1 (en) * 2008-02-22 2011-03-10 University Health Network MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells
JP5872805B2 (ja) 2011-07-07 2016-03-01 花王株式会社 Ｍｆａｐ−４産生促進剤
US9988442B2 (en) * 2013-01-23 2018-06-05 Syddansk Universitet MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors
WO2016008498A1 (en) 2014-07-17 2016-01-21 Syddansk Universitet Mfap4 binding antibody blocking the interaction between mfap4 and integrin receptors
CN106771201A (zh) * 2016-12-05 2017-05-31 江西惠肽生物科技有限公司 用于肝纤维化诊断试剂盒及其检测方法

Also Published As

Publication number Publication date
EP3704147A1 (en) 2020-09-09
CN111315771B (zh) 2023-10-27
CN111315771A (zh) 2020-06-19
AU2018359635A1 (en) 2020-05-07
AU2018359635B2 (en) 2024-11-14
JP7382343B2 (ja) 2023-11-16
US11993649B2 (en) 2024-05-28
AU2018359635A2 (en) 2020-05-21
US20230047179A1 (en) 2023-02-16
JP2021513360A (ja) 2021-05-27
WO2019086580A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
US20240174740A1 (en) Multispecific antibodies that target hptp-beta (ve-ptp) and vegf
JP2022101694A (ja) ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
TW202528344A (zh) 眼科疾病之個人化治療
US12570733B2 (en) Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
US20240343791A1 (en) Bispecific fusion polypeptide and application thereof
TW202228790A (zh) 用於長效經眼遞送之非共價蛋白質－玻尿酸結合物
WO2022059800A1 (en) Bispecific binding molecules against vegf and ang2
CA2915386A1 (en) Cb1 receptor antigen-binding proteins and uses thereof
US11993649B2 (en) Antibodies against MFAP4
TW202246351A (zh) Htra1結合劑及其使用方法
JP6921943B2 (ja) 増加した眼球保持を伴う眼科用融合タンパク質
KR20220029524A (ko) 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
JP2025534971A (ja) 安定かつ強力な抗血管新生ｓｃｆｖフラグメントおよびそのｖｅｇｆ拮抗薬としての使用
JP2025541722A (ja) Ｃ５／ｖｅｇｆ二重特異性結合分子
TW202604956A (zh) Ang2/vegf 雙特異性結合分子
HK40126782A (en) C5/vegf bispecific binding molecules
KR20220029343A (ko) 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231031

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250416

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250718

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250718

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251020

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251020

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260602

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260603